Emergency department use by patients with prurigo nodularis in the United States - 10/03/21
Doi : 10.1016/j.jaad.2020.06.1002
Katherine A. Whang, BS a, Sylvie Gabriel, MD, MBA b, Rajeev Chavda, MD b, Shawn G. Kwatra, MD a, c, ⁎ 
a Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland
b Galderma Presciption GBU, La Tour-de-Peilz, Switzerland
c Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland
∗Correspondence to: Shawn G. Kwatra, MD, Cancer Research Building II, Johns Hopkins University School of Medicine, Ste 206, 1550 Orleans St, Baltimore, MD 21231Cancer Research Building IIJohns Hopkins University School of MedicineSte 206, 1550 Orleans StBaltimoreMD21231
| Funding sources: Dr Kwatra received a research grant from Galderma, which is developing the investigational agent nemolizumab, received a grant from the Skin of Color Society, and is a recipient of a Medical Dermatology Career Development Award from the Dermatology Foundation. |
|
| Conflicts of interest: Dr Kwatra is an advisory board member for Pfizer Inc, Galderma, Regeneron Pharmaceuticals, and Menlo Therapeutics. Drs Gabriel and Chavda are employed by Galderma. Author Whang has no conflicts of interest to declare. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 84 - N° 4
P. 1138-1140 - avril 2021 Retour au numéro
Article précédent
- Comparison of different incremental dose regimens of narrow-band ultraviolet B in skin types III to V: A prospective, randomized, single-blind, parallel study in patients with psoriasis
- Yingyuan Yu, Xuemei Yi, Yi Zhang, Ning Yu, Qian Yu, Qianlian Le, Zeyu Chen, Yangfeng Ding, Yuling Shi
- Efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients: Open-label phase 4 study
- Lawrence F. Eichenfield, Boni Elewski, Jeffrey L. Sugarman, Ted Rosen, Tracey C. Vlahovic, Aditya K. Gupta, Radhakrishnan Pillai, Eric Guenin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?